What makes a device a valid predicate for a 510(k)?

A valid predicate is a legally marketed device that shares your device's intended use. It can be a pre-1976 device, a device cleared through a prior 510(k), or a device reclassified from Class III. The predicate must be in legal commercial distribution or have been legally marketed at some point. A device that was recalled for safety reasons or withdrawn from the market is not automatically invalid as a predicate, but using it requires a careful explanation of why those issues do not apply to your device.

Can I use more than one predicate device in a 510(k)?

Yes. FDA permits multiple predicates when different cleared devices support different aspects of your submission, such as one predicate for intended use and another for a specific technological feature. The key rule is that the intended use must be consistent across all predicates cited. You cannot split the intended use itself between predicates.

What is "predicate creep" and why does it matter?

Predicate creep refers to a series of 510(k)s in which each submission cited the prior one as a predicate, with each iteration drifting slightly from the original cleared device. Over time, the most recent device in the chain may bear little resemblance to the original. FDA has raised concerns about predicate creep in several device categories. Before you cite a predicate, review its own 510(k) history to understand how far it has drifted from its own predicate.

What happens if FDA disagrees with my predicate choice?

FDA can issue a Not Substantially Equivalent (NSE) determination or send an Additional Information (AI) request asking you to clarify or change your predicate. An NSE is not a safety finding; it means FDA does not agree that your device is substantially equivalent to the predicate you cited. At that point you can submit a new 510(k) with a different predicate, or evaluate whether the De Novo pathway is more appropriate. A 513(g) Request for Information can also help clarify how FDA views your device classification and applicable requirements, though it is an information request rather than an appeal of the NSE decision itself.

Is a Pre-Submission meeting required before choosing a predicate?

No, a Q-Sub is voluntary. But for any device with novel features, an unfamiliar product code, or a multi-predicate strategy, the Q-Sub is one of the most cost-effective steps in the program. FDA provides written feedback within 70 calendar days of a meeting request (as of July 2026, per MDUFA V commitments), and that feedback is on the record.

Can I use a device cleared in another country as a predicate?

No. The predicate must be legally marketed in the United States. EU CE-marked or Health Canada-licensed devices are not valid predicates under the 510(k) program.

How early in development should I identify my predicate?

As early as possible, ideally during or immediately after feasibility. Predicate selection affects device design, testing protocols, and intended use language. Discovering a predicate problem after design freeze is significantly more expensive than discovering it before. Many regulatory consultants recommend predicate research as a first-week activity when a new program starts.

How to Choose a Predicate Device for Your 510(k) Submission

Direct answer: A predicate device is a legally marketed medical device you cite in a 510(k) to demonstrate that your new device is substantially equivalent in intended use and technological characteristics. The right predicate has the same intended use as your device, a clean regulatory history, and no associated design-related recalls. FDA issued draft guidance on predicate selection in September 2023 recommending predicates that were cleared using well-established methods and meet or exceed expected safety and performance standards. (As of July 2026.)

The 510(k) pathway depends on a single legal concept: substantial equivalence. Under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), a device is substantially equivalent to a predicate if it has the same intended use and either the same technological characteristics or different characteristics that do not raise new questions of safety and effectiveness, and the device is at least as safe and effective as the predicate (as of July 2026, per 21 CFR Part 807 and FDA's Substantial Equivalence guidance).

A legally marketed predicate can be a device cleared through a prior 510(k), a device in commercial distribution before May 28, 1976 (a "pre-amendment" device), a device reclassified down from Class III to Class II or I, or a device previously found substantially equivalent through another 510(k).

Predicate selection is not a clerical step. The predicate you choose shapes the questions FDA will ask, the data package you will need to build, and whether a submission holds together at all. Teams that treat predicate selection as an afterthought regularly receive Additional Information (AI) requests or Not Substantially Equivalent (NSE) decisions that could have been avoided with earlier strategic analysis.

How FDA Evaluates Substantial Equivalence

Step 1: Same intended use? If the intended use differs, the submission fails at step one. Intended use encompasses the disease or condition the device addresses and the patient population it targets. Minor wording differences can be acceptable; a material difference in clinical purpose is not.

Step 2: Same or different technological characteristics? If your device has the same technological characteristics as the predicate, equivalence is straightforward (assuming the same intended use). If technological characteristics differ, you must demonstrate that the differences do not raise new questions of safety and effectiveness and that the device is at least as safe and effective as the predicate. This is where performance testing, bench data, biocompatibility data, and sometimes clinical data become part of the argument.

FDA published draft guidance in September 2023 titled Best Practices for Selecting a Predicate Device to Support a Premarket Notification (510(k)) Submission (docket FDA-2023-D-3134). This guidance remains draft as of July 2026; it gives concrete criteria for evaluating candidate predicates.

The Four Qualities of a Strong Predicate

1. Matching intended use

The predicate must share your device's intended use. This includes the clinical indication, the intended patient population, the environment of use (home, clinical, surgical), and the user type (layperson, trained clinician). A device intended for the same anatomical location but a different clinical purpose is not a viable predicate even if the hardware looks similar.

2. Clean regulatory record

FDA's September 2023 draft guidance recommends predicates that were cleared using well-established, recognized testing methods, are not subject to a design-related recall, have no unmitigated use-related safety issues, and were not withdrawn from the market for safety or effectiveness reasons. A predicate that carries safety history baggage does not disqualify itself automatically, but it creates additional scrutiny. FDA reviewers will examine whether the issues in the predicate's history apply to your device.

3. Manageable technological differences

The fewer unexplained technological differences between your device and the predicate, the cleaner the equivalence argument. Large differences require a heavier data package and increase the likelihood that reviewers will conclude the differences raise new questions that cannot be closed by performance testing alone.

4. Current market presence

A predicate still in active distribution signals that the technology remains relevant and clinically accepted. An obsolete predicate is still legally usable, but FDA may scrutinize why you chose a device no longer on the market and whether the regulatory conditions under which it was cleared still apply.

Using Multiple Predicates

FDA explicitly permits the use of more than one predicate in a single submission. Multiple predicates are most commonly used when you need one predicate for intended use and a second for a specific technological feature your device shares with a different cleared device, or when the device is a combination of technologies, each of which has a closer comparator in a different cleared device.

The critical constraint: you cannot split your intended use across multiple predicates. The intended use must be the same for all predicates cited. FDA's Content of a 510(k) guidance makes clear that the intended use comparison must be coherent across the submission. Splitting the intended use across predicates is not a multi-predicate strategy; it is a signal that your device is novel in ways that the 510(k) pathway may not accommodate.

When using multiple predicates, write a clear rationale for each one. Explain which characteristic each predicate supports and why that predicate is the best comparison point for that characteristic. Disorganized multi-predicate submissions are a common source of AI requests because reviewers cannot follow the equivalence logic.

Split Predicates: What They Are and When They Fail

A split predicate approach attempts to use one predicate to establish intended use and a different predicate to establish technological characteristics. FDA has historically accepted this approach in limited circumstances, particularly when a device combines elements of two separate, established device types.

The approach fails when the intended use of the two predicates is not the same (meaning you are implicitly arguing that your device serves two different intended uses), when the combination of features from two predicates produces a device that is functionally novel and raises new questions neither predicate's data can address, or when FDA concludes that the combined device is a new type of device more appropriately reviewed through De Novo.

If you are considering a split predicate, a Pre-Submission (Q-Sub) meeting with FDA is the right place to test the strategy before investing in a full data package. See the companion lesson on FDA Pre-Submission (Q-Sub) meetings for how to structure that conversation.

When a Predicate Becomes a Trap

Not all legally marketable predicates make good predicates. Teams sometimes lock onto a predicate early in development and discover problems only after substantial investment.

Trap 1: The recalled predicate. If your predicate has a Class I or Class II recall associated with its design (not just a manufacturing defect), FDA will scrutinize whether your device shares the same design feature that drove the recall. Using a recalled predicate is not prohibited, but it requires a clear explanation of why the recall issue does not apply to your device.

Trap 2: The outdated performance standard predicate. Some older cleared devices were cleared before current consensus standards existed for their device type. Citing them as predicates can leave your submission without an established performance baseline. FDA may ask you to meet current standards that your predicate was never tested against.

Trap 3: The narrow-indication predicate. A predicate with a narrowly written intended use can force your device into a narrower indication than your marketing strategy requires. You may clear the device but be unable to promote it for all the uses you intended.

Trap 4: The predicate that triggers a different classification. Some predicate selection choices inadvertently link your device to a product code with more demanding special controls than the product code you expected to fall under. Always confirm the product code and associated special controls before committing to a predicate.

Trap 5: The predicate creep chain. Predicate creep occurs when a series of 510(k)s have each drifted slightly from the original predicate, accumulating technological differences over time. Citing the most recent link in that chain may mean your predicate's own substantial equivalence rests on a shaky foundation. FDA has flagged predicate creep as a concern, particularly in rapidly evolving device categories. Reviewing the predicate's own 510(k) history before citing it is good practice.

How to Research Candidate Predicates

FDA's 510(k) Premarket Notification database is the primary research tool. Search by product code, device name, or applicant. For each candidate predicate, review the predicate's own 510(k) summary or statement (publicly available), the device's recall history in FDA's recall database, whether the product code still applies or has been reclassified, and the special controls attached to that product code.

This research belongs early in the development program, not six months before you plan to submit. Predicate selection affects device design, testing protocols, and labeling. Discovering a predicate problem after you have locked specifications is expensive.

The Role of a Pre-Submission Meeting in Predicate Strategy

FDA's Pre-Submission (Q-Sub) program lets sponsors get written FDA feedback on a proposed predicate strategy before submission. A well-structured Q-Sub can confirm whether FDA agrees with your proposed predicate, whether a multi-predicate or split-predicate approach is acceptable, what performance data FDA expects to close the equivalence argument, and whether the intended use comparison will hold under review.

Q-Sub meetings do not guarantee acceptance of a later submission, but they significantly reduce the probability of unexpected NSE decisions. For a regulatory program of any complexity, the Q-Sub investment before submission pays for itself many times over.

How Marketing Strategy Connects to Predicate Strategy

The intended use you write into your 510(k) becomes the boundary of your cleared labeling. It also becomes the boundary of your marketing claims. A device cleared with a narrow intended use cannot be promoted for uses outside that clearance without triggering misbranding concerns and potentially requiring a new submission.

This means predicate selection and commercial strategy need to be aligned from the beginning of the program. A predicate that delivers a narrow clearance limits what Buzzbox Media and your commercial team can say in marketing materials, sales training, and promotional content. Understanding that boundary before clearance is how you build a marketing program that scales without compliance risk.

For more on how cleared labeling boundaries affect what you can and cannot say in promotion, see the companion article on medical device labeling and IFU requirements and our service overview at Buzzbox Media medical device marketing.